---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-23-000038"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:37:01.828478+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q3 revenue plunges to $6.6M from $101M; net loss $0.10/sh vs prior year profit

## Summary
- Total revenue $6.6M, down 93.5% from $101.4M in Q3 2022.
- Net loss of $28.6M ($0.10 loss per share) vs net earnings of $26.6M ($0.09 EPS) in Q3 2022.
- Cumulative partnered program starts reached 110, up 20% YoY; 10 molecules in clinic.
- Two AbCellera-led programs advanced into IND-enabling studies.
- Cash, cash equivalents, and marketable securities $813.0M; R&D expenses $37.9M.

## SEC filing metadata
- accession: 0001703057-23-000038
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/0001703057-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/abcl-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-23-000038
- JSON: https://secwatch.observer/filing/0001703057-23-000038.json
- Plain text: https://secwatch.observer/filing/0001703057-23-000038.txt

## Key facts
- Earnings Releases
  AbCellera Biologics Inc. reported the quarter ended September 30, 2023 results: revenue $6.6 million, net income net loss of $28.6 million, EPS $(0.10) per share on a basic and diluted basis.
  - Period: the quarter ended September 30, 2023
  - Revenue: $6.6 million
  - Net income: net loss of $28.6 million
  - EPS: $(0.10) per share on a basic and diluted basis
  - Result: reported results
  source text: value, both through strategic partnerships, and through internal discovery and development of potential first-in-class antibody therapies.” Q3 2023 Business Summary ● Earned $6.6 million in total revenue. ● Generated a net loss of $28.6 million, compared to net earnings of $26.6 million in Q3 2022. ● Reached a cumulative total of 182 programs under contract with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/0001703057-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.